Literature DB >> 32047957

Activation of TLR4 signaling inhibits progression of osteosarcoma by stimulating CD8-positive cytotoxic lymphocytes.

Kenichiro Yahiro1, Yoshihiro Matsumoto2, Hisakata Yamada1, Makoto Endo1, Nokitaka Setsu1, Toshifumi Fujiwara1, Makoto Nakagawa1,3, Atsushi Kimura1, Eijiro Shimada1, Seiji Okada4, Yoshinao Oda5, Yasuharu Nakashima1.   

Abstract

BACKGROUND: Osteosarcoma (OS) is the most common malignant bone tumor and the prognosis of advanced cases is still poor. Recently, there have been several reports suggesting the relationship between innate immunity and OS, but the detailed mechanism is unknown. We demonstrate the relationship between OS and Toll-like receptor 4 (TLR4) which is one of the most important factors in innate immunity.
METHODS: We established a syngenic mouse tumor model using C3H/HeN, C3H/HeJ mouse and a highly metastatic OS cell line, LM8. TLR4 activation with lipopolysaccharide (LPS) was performed on both mice and its influence on the progression of OS was evaluated. We also performed CD8 + cells depletion to examine the influence on TLR4 activation effects.
RESULTS: Tumor volume of C3H/HeN mice was significantly smaller and overall survival of C3H/HeN mice was significantly longer than C3H/HeJ mice. We found more CD8+ cells infiltrating in lung metastases of C3H/HeN mice and depletion of CD8+ cells canceled the antitumor effects of LPS.
CONCLUSION: TLR4 activation by LPS increased CD8+ cells infiltrating into lung metastases and suppressed OS progression in the mouse model. TLR4 activation may suppress the progression of OS via stimulating CD8+ cells and can be expected as a novel treatment for OS.

Entities:  

Keywords:  CD8-positive lymphocytes; Innate immunity; Osteosarcoma; Prognosis; Toll-like receptor 4

Mesh:

Substances:

Year:  2020        PMID: 32047957     DOI: 10.1007/s00262-020-02508-9

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  13 in total

Review 1.  Immune Microenvironment in Osteosarcoma: Components, Therapeutic Strategies and Clinical Applications.

Authors:  Tianyi Zhu; Jing Han; Liu Yang; Zhengdong Cai; Wei Sun; Yingqi Hua; Jing Xu
Journal:  Front Immunol       Date:  2022-06-01       Impact factor: 8.786

2.  Apoptosis-related genes-based prognostic signature for osteosarcoma.

Authors:  Fei Yang; Yi Zhang
Journal:  Aging (Albany NY)       Date:  2022-05-03       Impact factor: 5.955

3.  Immunotherapy for osteosarcoma.

Authors:  Kenichiro Yahiro; Yoshihiro Matsumoto
Journal:  Hum Vaccin Immunother       Date:  2020-12-24       Impact factor: 3.452

4.  The versatile electric condition in mouse embryos for genome editing using a three-step square-wave pulse electroporator.

Authors:  Kenta Nakano; Yukiko Shimizu; Tetsuya Arai; Taketo Kaneko; Tadashi Okamura
Journal:  Exp Anim       Date:  2021-12-07

5.  Development of a prognostic gene signature based on an immunogenomic infiltration analysis of osteosarcoma.

Authors:  Yiyang Yu; Hongliang Zhang; Tingting Ren; Yi Huang; Xin Liang; Wei Wang; Jianfang Niu; Yu Han; Wei Guo
Journal:  J Cell Mol Med       Date:  2020-08-21       Impact factor: 5.310

6.  Establishment of Immune-related Gene Pair Signature to Predict Lung Adenocarcinoma Prognosis.

Authors:  Xueping Jiang; Yanping Gao; Nannan Zhang; Cheng Yuan; Yuan Luo; Wenjie Sun; Jianguo Zhang; Jiangbo Ren; Yan Gong; Conghua Xie
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

7.  Development of an immune-related signature for predicting survival outcome and immunotherapy response in osteosarcoma.

Authors:  Qinghua Wang; Wenjing Zhang; Yuxian Guo; Yuting Li; Kaifeng Fu
Journal:  Aging (Albany NY)       Date:  2021-11-08       Impact factor: 5.682

8.  CALR-TLR4 Complex Inhibits Non-Small Cell Lung Cancer Progression by Regulating the Migration and Maturation of Dendritic Cells.

Authors:  Ruo Chen; Min Huang; Xu Yang; Xiao-Hong Chen; Ming-Yan Shi; Zhuo-Fan Li; Zhi-Nan Chen; Ke Wang
Journal:  Front Oncol       Date:  2021-10-01       Impact factor: 6.244

9.  Tumor infiltrating immune cells (TIICs) as a biomarker for prognosis benefits in patients with osteosarcoma.

Authors:  Ying Chen; Bo Zhao; Xiaohu Wang
Journal:  BMC Cancer       Date:  2020-10-21       Impact factor: 4.430

10.  TYROBP, TLR4 and ITGAM regulated macrophages polarization and immune checkpoints expression in osteosarcoma.

Authors:  Tuo Liang; Jiarui Chen; GuoYong Xu; Zide Zhang; Jiang Xue; Haopeng Zeng; Jie Jiang; Tianyou Chen; Zhaojie Qin; Hao Li; Zhen Ye; Yunfeng Nie; Chong Liu; Xinli Zhan
Journal:  Sci Rep       Date:  2021-09-29       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.